171 related articles for article (PubMed ID: 21155191)
1. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
Skorupski KA; Rodriguez CO; Krick EL; Clifford CA; Ward R; Kent MS
Vet Comp Oncol; 2009 Jun; 7(2):139-44. PubMed ID: 19453368
[TBL] [Abstract][Full Text] [Related]
3. CCNU for the treatment of dogs with histiocytic sarcoma.
Skorupski KA; Clifford CA; Paoloni MC; Lara-Garcia A; Barber L; Kent MS; LeBlanc AK; Sabhlok A; Mauldin EA; Shofer FS; Couto CG; Sørenmo KU
J Vet Intern Med; 2007; 21(1):121-6. PubMed ID: 17338159
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
Mason SL; Finotello R; Blackwood L
Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.
Cannon C; Borgatti A; Henson M; Husbands B
J Small Anim Pract; 2015 Jul; 56(7):425-9. PubMed ID: 25828786
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs.
Kezer KA; Barber LG; Jennings SH
Vet Comp Oncol; 2018 Mar; 16(1):77-80. PubMed ID: 28419676
[TBL] [Abstract][Full Text] [Related]
7. Treatment of canine mast cell tumors with CCNU (lomustine).
Rassnick KM; Moore AS; Williams LE; London CA; Kintzer PP; Engler SJ; Cotter SM
J Vet Intern Med; 1999; 13(6):601-5. PubMed ID: 10587263
[TBL] [Abstract][Full Text] [Related]
8. Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
Treggiari E; Cossu G; Valenti P; Taylor A
Vet Comp Oncol; 2022 Sep; 20(3):577-586. PubMed ID: 35249267
[TBL] [Abstract][Full Text] [Related]
9. Lomustine chemotherapy for the treatment of presumptive haemophagocytic histiocytic sarcoma in Flat-coated Retrievers.
Elliott J
Aust Vet J; 2018 Dec; 96(12):502-507. PubMed ID: 30478839
[TBL] [Abstract][Full Text] [Related]
10. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
11. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
[TBL] [Abstract][Full Text] [Related]
12. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.
Moore AS; London CA; Wood CA; Williams LE; Cotter SM; L'Heureux DA; Frimberger AE
J Vet Intern Med; 1999; 13(5):395-8. PubMed ID: 10499719
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes in dogs with localized splenic histiocytic sarcoma treated with splenectomy with or without adjuvant chemotherapy.
Latifi M; Tuohy JL; Coutermarsh-Ott SL; Klahn SL; Leeper H; Dervisis N
J Vet Intern Med; 2020 Nov; 34(6):2645-2650. PubMed ID: 32986268
[TBL] [Abstract][Full Text] [Related]
14. Outcome in dogs with curative-intent treatment of localized primary pulmonary histiocytic sarcoma.
Murray CA; Willcox JL; De Mello Souza CH; Husbands B; Cook MR; Clifford C; Leeper H; Pellin M; Richardson D; Herrera CL; Krick E; McMillan S; Al-Nadaf S; Skorupski KA
Vet Comp Oncol; 2022 Jun; 20(2):458-464. PubMed ID: 34878710
[TBL] [Abstract][Full Text] [Related]
15. CCNU in the treatment of canine epitheliotropic lymphoma.
Williams LE; Rassnick KM; Power HT; Lana SE; Morrison-Collister KE; Hansen K; Johnson JL
J Vet Intern Med; 2006; 20(1):136-43. PubMed ID: 16496933
[TBL] [Abstract][Full Text] [Related]
16. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine)*.
Hosoya K; Lord LK; Lara-Garcia A; Kisseberth WC; London CA; Couto CG
Vet Comp Oncol; 2009 Dec; 7(4):244-55. PubMed ID: 19891695
[TBL] [Abstract][Full Text] [Related]
18. Nimustine Treatment of 11 Cases of Canine Histiocytic Sarcoma.
Tani H; Kurita S; Miyamoto R; Sawada H; Fujiwara-Igarashi A; Michishita M; Azakami D; Hasegawa D; Tamura K; Bonkobara M
J Am Anim Hosp Assoc; 2020; 56(3):146. PubMed ID: 32182105
[No Abstract] [Full Text] [Related]
19. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
Hosoya K; Kisseberth WC; Alvarez FJ; Lara-Garcia A; Beamer G; Stromberg PC; Couto CG
J Am Anim Hosp Assoc; 2009; 45(1):14-8. PubMed ID: 19122059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
